Introduction: The Compounding Shift in 2025 The story of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an intriguing tale of success, drug shortage and unintentional consequences
Patients currently receiving compounded TB-500 should ask their prescriber to submit any adverse events through the FDA MedWatch portal, as voluntary reporting is the only mechanism generating real-world safety data on this peptide
Related Weight Loss Research Compounds Semaglutide 20mg GLP-1 Receptor Agonist Tirzepatide 30mg Dual GLP-1/GIP Agonist Retatrutide 20mg Triple Agonist Research Peptide Retatrutide 30mg Triple Agonist Research Peptide AOD-9604 5mg Fat-Metabolism Research Fragment Scientific References Jastreboff et al
Common Side Effects Nausea (very common approximately 40% of patients) Flushing Injection site reactions: pain, redness, bruising Headache Vomiting Cough Fatigue Hot flush Skin hyperpigmentation (focal dark patches, especially with repeated use) Seek Immediate Medical Attention For Severe, persistent increase in blood pressure Chest pain, shortness of breath, or irregular heartbeat Signs of severe allergic reaction Persistent or worsening skin darkening Drug Interactions Naltrexone: Bremelanotide may significantly decrease naltrexone exposure, potentially reducing its effectiveness for alcohol/opioid use disorder treatment Orally administered medications: Slowed gastric emptying may affect absorption of other oral drugs Use in Pregnancy Bremelanotide is contraindicated in pregnancy
Together, youll review your medical history and establish a personalized treatment plan
